ARTICLE | Emerging Company Profile
Cartography emerges from stealth to map cancer antigens
With a $51M series A led by 8VC, single cell profiling company aims to discover broadly expressed targets unique to tumor cells
July 20, 2022 11:40 PM UTC
Cartography is expanding the world of tumor antigen targets for CAR T cells and other new modality therapies with a platform that can pick up on targets missed by conventional screening methods.
San Francisco Bay Area-based Cartography Biosciences Inc. emerged from stealth on Tuesday with $57 million in total funding and cell therapy pioneer Carl June heading up its scientific advisory board. The funding includes $51 million in a series A round led by new investor 8VC...